Viatris Patent-Cliff Exposure & CMS Drug Spending Portfolio

Viatris (Canonsburg, PA): 112 reconciled FDA prescription therapies (4.6% 2025 to 2030 cliff risk), $1.27B 2024 CMS Part D & Medicaid spend, and 222 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterCanonsburg, PA
Reconciled FDA Portfolio Therapies112
2025 to 2030 Patent-Cliff Revenue Exposure4.6%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$1.27B
2024 Medicare Part D Spend$868.5M
2024 Medicaid Spend$403.8M
California HCAI SB 17 Filings222 WAC filings (max 29.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.